Yes. An RSV vaccine can help immunocompromised adults by lowering the chance of severe respiratory syncytial virus (RSV) illness and hospitalization, although protection may be weaker when the immune system is suppressed. The Infectious Diseases Society of America recommends RSV vaccination for immunocompromised adults, but the best timing and eligibility depend on age, treatment, transplant history, and local guidance. A clinician can help weigh expected benefit and risks.
Why is RSV vaccination important for immunocompromised adults?
Respiratory syncytial virus (RSV) is a common virus that affects the lungs and airways. It often causes cold-like symptoms, such as a runny nose, cough, and congestion. However, some infections can lead to pneumonia, breathing difficulties, and hospitalization. Adults with weakened immune systems are at greater risk of serious RSV illness, particularly when their immune defenses are significantly reduced.
According to the U.S. Centers for Disease Control and Prevention (CDC), adults with weakened immune systems are among the groups at increased risk of severe RSV disease. This risk is especially relevant for people receiving treatments that suppress immune function or those whose underlying illnesses interfere with their ability to fight infections.
How does the RSV vaccine help when the immune system is weakened?
RSV vaccines train the immune system to recognize parts of the virus and produce a protective immune response. If an immunized person encounters RSV later, this response may help reduce the likelihood of serious lower respiratory tract disease, which affects the lungs and smaller airways. Vaccination does not guarantee that a person will avoid infection, and it cannot eliminate every risk of severe illness.
The Infectious Diseases Society of America (IDSA), in its 2026 clinical guidelines, recommends RSV vaccination for immunocompromised adults. Its evidence review found an estimated vaccine effectiveness of 68% against RSV-associated hospitalization across five studies involving immunocompromised people. This pooled estimate supports vaccination as an important preventive measure, but it does not predict the exact protection an individual will receive. Some people may develop a weaker response because of their illness or treatment.
Which immunocompromised adults may benefit from RSV vaccination?
Immunocompromised adults include people whose immune systems are weakened by a medical condition, a medical procedure, or treatment. The degree of immune suppression differs from one person to another. Examples of conditions or treatments that may place adults in this group include:
- Organ transplantation: People who have received, or are preparing for, a kidney, lung, heart, liver, or other solid-organ transplant may take medicines that suppress immune activity.
- Blood cancers: Certain leukemias, lymphomas, and other blood cancers can affect immune function, as can their treatments.
- Cancer treatment: Chemotherapy and some other treatments may weaken the immune system.
- Stem cell transplantation or CAR T-cell therapy: These treatments can cause periods of substantial immune suppression.
- HIV: HIV can impair immune defenses, especially when immune function is substantially reduced.
- Autoimmune diseases treated with immunosuppressants: Certain medicines used for conditions such as rheumatoid arthritis or other inflammatory disorders can reduce the body's immune response.
- Primary immunodeficiency: Some inherited conditions affect the immune system's ability to protect against infections.
These examples do not mean that everyone in each group has the same level of risk or will respond equally well to vaccination. The type of illness, medication, treatment schedule, and stage of recovery all influence the decision. People who have multiple risk factors, such as immune suppression combined with chronic lung or heart disease, may need particularly careful prevention planning.
Who is eligible for an RSV vaccine?
Eligibility depends on age, individual risk, the specific vaccine, and the recommendations in the country where a person receives care. In the United States, the CDC's adult RSV vaccination guidance, updated in February 2026, recommends one dose for all adults aged 75 years and older and for adults aged 50–74 years who are at increased risk of severe RSV illness. Moderate or severe immune compromise is among the qualifying risk factors for adults in the 50–74 age group.
For younger adults, the distinction between regulatory approval and routine vaccination recommendations matters. The U.S. Food and Drug Administration's information on Arexvy includes adults aged 18–59 who are at increased risk of RSV-associated lower respiratory tract disease. However, the CDC's routine recommendation does not automatically extend to every immunocompromised adult under 50. The IDSA's 2026 specialty guideline recommends vaccination for immunocompromised adults aged 18 and older, creating an important distinction between specialist guidance and routine national recommendations. Younger adults should discuss the applicable recommendation and approved vaccine options with their treating clinician.
In other countries, eligibility, approved age ranges, and access may differ. A healthcare professional can check the current local guidance and determine whether vaccination is appropriate for an individual patient.
When should immunocompromised adults receive the RSV vaccine?
Timing matters because some treatments can reduce the immune response to a vaccine. When possible, vaccination should be planned before an expected period of increased exposure to RSV and coordinated with cancer therapy, immune-suppressing medicines, or transplantation. In the continental United States, the CDC identifies late summer and early fall, generally August through October, as a useful period before RSV typically begins spreading widely. The best timing elsewhere depends on local RSV circulation.
The IDSA's guidance for immunocompromised patients emphasizes individualized timing. For example, transplant candidates, particularly people awaiting a lung transplant, should ideally be vaccinated before transplantation. For people receiving a hematopoietic cell transplant or CAR T-cell therapy, the guideline recommends vaccination at least three months afterward; following B-cell-depleting treatment, it recommends waiting at least six months. These are specialist recommendations, and earlier vaccination may sometimes be considered when the risk of infection is high.
People receiving chemotherapy or immunosuppressive treatment for autoimmune disease should discuss their treatment schedule with their specialist before arranging vaccination. If treatment is about to begin, there may be an opportunity to vaccinate beforehand. However, vaccination should not be delayed indefinitely while waiting for an ideal window. The treating team can balance the possibility of a stronger immune response against the risk of remaining unprotected.
Does the RSV vaccine work if immune function is significantly reduced?
It may still provide useful protection, but the response can vary. Some immunocompromised adults develop enough of an immune response to reduce the risk of serious RSV disease, while others may have a less effective response. This is an important consideration for people receiving B-cell-depleting medicines, those undergoing cancer treatment, and transplant recipients receiving strong immunosuppression.
Current evidence supports vaccination, but research continues to examine how well individual vaccine products work across different immunocompromised groups and how long protection lasts. The available evidence does not establish that one RSV vaccine is best for every immunocompromised adult. Vaccine selection should take account of the person's age, clinical circumstances, locally approved products, and current recommendations.
What side effects and safety concerns should patients know about?
Most reported RSV vaccine side effects are temporary. They may include pain or tenderness at the injection site, tiredness, headache, muscle aches, joint pain, or nausea. These effects generally settle without specific treatment. A person's underlying medical condition and other medicines may influence how vaccination is planned, but having a weakened immune system does not automatically mean that an RSV vaccine is unsuitable.
The CDC's RSV vaccine safety information describes a possible increased risk of Guillain-Barré syndrome (GBS), a rare neurological disorder, following vaccination with Pfizer's Abrysvo and GSK's Arexvy. Based on available monitoring data, the estimated excess risk was about 10 cases per million vaccinated adults aged 60 and older. The evidence remains under review, and this estimate should not be assumed to apply directly to younger adults or every immunocompromised group.
Severe allergic reactions are rare but require immediate medical attention. Before vaccination, patients should tell their healthcare professional about previous serious allergic reactions to vaccines or their ingredients, relevant neurological history, current illness, and planned changes in immunosuppressive treatment. A clinician can review the potential benefits and risks in the context of the patient's health and treatment history.
Is one RSV vaccine dose enough?
For most eligible adults, current U.S. CDC recommendations call for a single dose rather than an annual RSV vaccination. A person who has already received an RSV vaccine should not routinely receive another dose under the CDC's current general adult guidance. The need for additional doses is still being studied, particularly in people with weakened immune systems.
The IDSA's 2026 guidance allows additional doses to be considered individually in certain immunocompromised patients, including some who were vaccinated at a suboptimal time around transplantation or immune-suppressing treatment. This is not a recommendation for everyone to receive repeated doses. Patients should follow their specialist's advice and the applicable national guidance rather than arranging booster doses on their own.
What else can immunocompromised adults do to reduce RSV risk?
Vaccination is one part of prevention, not a guarantee against infection. Immunocompromised adults can also reduce exposure by avoiding close contact with people who are sick, improving indoor ventilation, washing hands regularly, and considering a well-fitting mask in crowded or poorly ventilated settings when respiratory viruses are circulating. Household members should remain up to date with vaccines for which they are eligible.
Anyone with a weakened immune system who develops new or worsening respiratory symptoms should contact a healthcare professional promptly, particularly if there is difficulty breathing, chest discomfort, confusion, or an inability to maintain adequate fluid intake. Early assessment may be especially important for people undergoing cancer treatment or recovering from transplantation.
The key takeaway: RSV vaccination can help protect immunocompromised adults against serious illness and hospitalization. Although the strength of protection varies, current specialist guidance supports vaccination for this group. The most appropriate vaccine and timing depend on age, immune status, treatment schedule, transplant history, and the recommendations that apply where the person receives care.